Date: 2025-09-21
Church & Dwight is a consumer products company known for Arm & Hammer, Trojan, OxiClean, and other household/personal care brands. Revenue ~$6B, stable but modest growth (~5–6% CAGR). Profitable with ~45% gross margins, ~9% net margin.
Business Model Simplicity
- Simple: Everyday essentials (toothpaste, detergent, condoms).
- Sustainable: Consumers rebuy products regardless of economic cycle.
- Growth reliant on acquisitions + strong brand positioning.
Durable Competitive Advantage (Moat)
- Moat Type: Brand equity + distribution.
- Arm & Hammer has 175+ years of recognition.
- However, moat is narrow compared to giants like Procter & Gamble.
Competitors & Positioning
- Main competitors: Procter & Gamble, Colgate-Palmolive, Unilever, Kimberly-Clark.
- Positioned as a value-focused brand house rather than a premium innovator.
- Market share smaller, but brands are entrenched.
Management
- History of steady acquisitions (~$1.6B net in 5yrs).
- Reasonably shareholder-friendly: dividend + share count slightly down (-1.44%).
- Not aggressive with buybacks, but consistent.
Valuation
- Current price is overvalued vs intrinsic.
- Trading at P/E 42 vs 5yr avg 33 therefore premium pricing.
Capital Efficiency
- ROIC ~10% > WACC (~8%) therefore value-accretive.
- Reasonable use of capital, but not best-in-class.
Free Cash Flow
- Strong and consistent ($930M TTM, ~$800M avg).
- Supports dividend easily.
Balance Sheet
- Current Ratio: 1.84 (below “ideal” 2.0, but adequate).
- Debt/Equity: unavailable, but LTL/5yr FCF = 3.92 → manageable.
- Not debt-heavy, but not pristine.
Earnings & Revenue Consistency
- Revenue growth consistent (~5–6% CAGR).
- Earnings growth less stable (net income has fallen).
Margin of Safety
- At current price: none. Needs to fall ~30% ($65–70 range) for safety.
Biggest Risks
- Overpaying for acquisitions.
- Rising competition from P&G/Unilever private labels.
- Margin pressure from inflation/commodities.
- Stagnant organic growth.
Dilution
- Share count decreasing (-1.44%).
- Shareholder-friendly.
Cyclical or Stable
- Stable: consumer staples perform relatively well in recessions.
5–10 Year Outlook
- Slow, steady growth (3–6% CAGR).
- Likely to rely on more acquisitions.
- Will remain a mid-tier household products player.
Buy if Market Closed 5 Years?
- Only if bought at undervalued price (~$65).
- At $90+, not attractive.
PEGY Meaning
- PEGY = 7.34, which is very expensive relative to growth + dividends.
- Suggests poor forward returns unless growth accelerates.
Capital Returns
- Dividend ~1.3%, sustainable.
- Buybacks minimal.
- Some reinvestment in acquisitions → value depends on price paid.
Mispricing?
- Market paying premium for “stability + brand safety.”
- Overlooking slowing earnings + weak organic growth.
Key Assumptions & Risks
- Assuming stable growth (5–6%) and margins hold.
- Risk: commodity inflation, poor M&A execution, stronger private labels.
Portfolio Fit
- Good as a defensive consumer staple.
- Not a high-growth play, more of a stability anchor.
Intrinsic Value Decision
- Intrinsic Value: ~$65–70/share
- Current Price: ~$90–95/share
- Action: SELL / AVOID new buys until it falls closer to $65.
Calculations
Intrinsic Value Estimates
- Discounted Cash Flow (DCF): ~$65 per share
- Market-Expected Value (MEV): ~$70 per share
- Current Price Range (Sep 2025): ~$90–95 per share
Conclusion: CHD is trading above intrinsic value by ~30–40%.
Key Values Used
- Revenue (TTM): $6.07B
- Net Income (TTM): $525.2M
- Free Cash Flow (TTM): $930.6M (5yr avg: $813.2M)
- Net Income Growth 5yr: negative (-196M)
- FCF Growth 5yr: negative (-100M)
- Revenue Growth (5yr CAGR): 5.72%
- ROIC: 10.54%
- WACC assumption: ~8%
- Terminal growth rate: 2.5%
PEGY Calculation
- P/E (TTM): 42.39
- Earnings Growth (5yr CAGR proxy): ~5.7%
- PEG = P/E ÷ Growth = 42.39 ÷ 5.7 = 7.43
- PEGY = PEG ÷ (1 + Dividend Yield) = 7.43 ÷ 1.0127 ≈ 7.34
PEGY well above 1 → suggests the stock is expensive relative to growth and dividends.
Weighted SWOT Analysis
| Factor | Strength/Weakness/Opportunity/Threat | Weight | Impact | Weighted Score |
|---|---|---|---|---|
| Brand Recognition (Arm & Hammer, Trojan, OxiClean) | Strength | 0.20 | 9 | 1.80 |
| Consistent FCF Generation | Strength | 0.15 | 8 | 1.20 |
| ROIC > WACC | Strength | 0.10 | 7 | 0.70 |
| Revenue Growth (5–6% CAGR) | Strength | 0.10 | 6 | 0.60 |
| High Valuation (P/E > 40) | Weakness | 0.20 | -9 | -1.80 |
| Earnings Decline (5yr net income down) | Weakness | 0.10 | -7 | -0.70 |
| Dependence on Acquisitions | Weakness | 0.05 | -6 | -0.30 |
| Emerging Market Expansion | Opportunity | 0.05 | 6 | 0.30 |
| Innovation in eco-friendly products | Opportunity | 0.05 | 5 | 0.25 |
| Competition from P&G, Unilever, Private Labels | Threat | 0.10 | -8 | -0.80 |
| Commodity Inflation & Margin Pressure | Threat | 0.05 | -6 | -0.30 |
Total Weighted Score = 1.95 (out of 5)
Interpretation: CHD is a moderately strong but overvalued company. Strengths keep it stable, but valuation + weak earnings growth hold it back.
Final Verdict:
- Intrinsic Value: ~$65
- Fair Value Range: $60–70
- Current Price: ~$90–95
- Decision: HOLD if owned, SELL/AVOID new buys until it drops closer to intrinsic.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
